{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:55:00Z","timestamp":1791219300429,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pioneer R & D Program of Zhejiang","award":["2023SDYXS0001"],"award-info":[{"award-number":["2023SDYXS0001"]}]},{"name":"Pioneer R & D Program of Zhejiang","award":["2022C03031"],"award-info":[{"award-number":["2022C03031"]}]},{"DOI":"10.13039\/100017239","name":"BeiGene Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eclinm.2025.103308","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:59:20Z","timestamp":1750751960000},"page":"103308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer"],"prefix":"10.1016","volume":"85","author":[{"given":"Qiang","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhuai","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-7397","authenticated-orcid":false,"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103308_bib1","series-title":"Cancer Stat Facts: Cervix Uteri","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103308_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015. CA A","volume":"66","author":"Chen","year":"2016","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103308_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1158\/1055-9965.EPI-22-0674","article-title":"Trend in cervical cancer incidence and mortality rates in China, 2006\u20132030: a bayesian age-period-cohort modeling study","volume":"32","author":"Yuan","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eclinm.2025.103308_bib4","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103308_bib5","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103308_bib6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103308_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103308_bib8","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.eclinm.2025.103308_bib9","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.3389\/fimmu.2018.03081","article-title":"Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer","volume":"9","author":"Georganaki","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103308_bib10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103308_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2023.10.694","volume":"34","author":"Oaknin","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103308_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.eclinm.2025.103308_bib13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab uniquely binds to the CC\u2019 loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.eclinm.2025.103308_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eclinm.2025.103308_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use","volume":"1","author":"Heidari","year":"2016","journal-title":"Res Integr Peer Rev"},{"key":"10.1016\/j.eclinm.2025.103308_bib16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103308_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/pst.1654","article-title":"Sample size calculation for the one-sample log-rank test","volume":"14","author":"Wu","year":"2015","journal-title":"Pharm Stat"},{"key":"10.1016\/j.eclinm.2025.103308_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103308_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103308_bib20","article-title":"AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer","volume":"39","author":"Wu","year":"2021","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.eclinm.2025.103308_bib21","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103308_bib22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eclinm.2025.103308_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103308_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10120-018-0845-7","article-title":"Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin","volume":"22","author":"Nishina","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.eclinm.2025.103308_bib25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00280-017-3422-6","article-title":"Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy","volume":"80","author":"Kadowaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103308_bib26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","article-title":"Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103308_bib27","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","article-title":"Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)","volume":"51","author":"Heinemann","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2025.103308_bib28","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/cncr.32114","article-title":"Association between depth of response and survival in patients with advanced-stage non\u2013small cell lung cancer treated with first-line chemotherapy","volume":"125","author":"Morgensztern","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2025.103308_bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21037\/tcr-20-2547","article-title":"A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors","volume":"10","author":"Xie","year":"2021","journal-title":"Transl Cancer Res TCR"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:39:17Z","timestamp":1768829957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025002408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"alternative-id":["S2589537025002408"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103308","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103308"}}